Story perspectives

Mounjaro: Weight Loss Breakthrough Outshines Ozempic

10/20/2025

28 3

Summary

Story summary

Mounjaro mimics glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to suppress appetite and regulate blood sugar, and studies show participants lost up to 22.5% of weight over 72 weeks, outperforming Ozempic.
Side effects include nausea and diarrhea, but are generally mild.
The market shows 39 new GLP-1 drugs, including oral options.
GLP-1 drugs may alter the brain's reward system to reduce cravings, a finding that requires more studies.

1 of 1

Story summary

Mounjaro mimics glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to suppress appetite and regulate blood sugar, and studies show participants lost up to 22.5% of weight over 72 weeks, outperforming Ozempic.
Side effects include nausea and diarrhea, but are generally mild.
The market shows 39 new GLP-1 drugs, including oral options.
GLP-1 drugs may alter the brain's reward system to reduce cravings, a finding that requires more studies.